Open AccessA New CD10 Antibody Inhibits the Growth of Malignant Mesothelioma
Author(s) -
Natsuko Mizutani,
Masaaki Abe,
Kazunori Kajino,
Satoshi Matsuoka
Publication year - 2021
Publication title -
monoclonal antibodies in immunodiagnosis and immunotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.309
H-Index - 36
ISSN - 2167-9436
DOI - 10.1089/mab.2020.0033
Subject(s) - mesothelioma , monoclonal antibody , antibody , cancer research , antigen , immunohistochemistry , medicine , cyclin d1 , immunology , microbiology and biotechnology , pathology , biology , cell cycle , cancer
Malignant mesotheliomas (MMs) are aggressive therapy-resistant tumors that generally have a poor prognosis. We previously reported the establishment of four new monoclonal antibodies (mAbs) for the diagnosis and treatment of MM. In this report, we characterized one of these antibodies, JMAM-1. The molecules whose antibodies were calibrated were picked up, transfected assuming CD10, and elucidated by fluorescence activated cell sorter. Survival experiments were performed using tumor-bearing mice model. JMAM-1 mAb was found to bind with CD10 antigen. The Kaplan–Meier survival curve showed a small but prolonged survival effect. JMAM-1 mAb-treated MSTO-211H cells showed increased cell cycle arrest involved by cyclin-dependent-kinase. JMAM-1 antibody has cytostatic effect and may be a candidate for the treatment of MM. Among mesothelioma, CD10-positive cases have been reported to have a poorer prognosis than negative cases, which can be used as a tool for diagnosis.